A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Study Details
Study Description
Brief Summary
This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL).
This is a 2-part study (dose escalation, cohort expansion) with sequential enrollment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1/Phase 2 |
Detailed Description
In Part 1, enrolled subjects will receive IV RNK05047 once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week). The dose-escalation phase will follow a standard 3+3 design, with 3 subjects enrolled into the first dosing cohort to receive RNK05047 at the starting dose of 0.75 mg/kg.
In Part 2, once RP2D has been established, additional subjects (3 to 5 cohorts of approximately 15 subjects per cohort) will be enrolled in the cohort-expansion phase of the study. Tumor types for these cohorts will be determined based on data from the dose-escalation phase of the study and emerging results from preclinical studies or other scientific data. These dose expansion cohorts in all groups may be done concurrently.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: RNK05047 Dose-escalation of RNK05047 IV infusion |
Drug: RNK05047
RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).
|
Outcome Measures
Primary Outcome Measures
- Part 1: Incidence of DLTs [through 1 cycle/4 weeks]
- Part 1: Incidence of TEAEs [through study completion, an average of 1 year]
- Part 2: Incidence of TEAEs [through study completion, an average of 1 year]
- Part 2: Objective response rate (ORR) based on RECIST 1.1/RECIL 2017 [through study completion, an average of 1 year]
- Part 2: Duration of response (DoR) based on RECIST 1.1/RECIL 2017 [through study completion, an average of 1 year]
- Part 2: Progression-free Survival (PFS) based on RECIST 1.1/RECIL 2017 [through study completion, an average of 1 year]
- Part 2: Disease Control Rate (DCR) based on RECIST 1.1/RECIL 2017 [through study completion, an average of 1 year]
Secondary Outcome Measures
- Part 1: Plasma concentration RNK05047 [Through Cycle 3/approximately 12 weeks]
- Part 1: ORR based on RECIST 1.1/RECIL 2017 [through study completion, an average of 1 year]
- Part 1: DoR based on RECIST 1.1/RECIL 2017 [through study completion, an average of 1 year]
- Part 1: PFS based on RECIST 1.1/RECIL 2017 [through study completion, an average of 1 year]
- Part 1: DCR based on RECIST 1.1/RECIL 2017 [through study completion, an average of 1 year]
- Part 2: Plasma concentration RNK05047 [Through Cycle 3/approximately 12 weeks]
- Part 2: Overall Survival (OS) [through study completion, an average of 1 year]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Pathologically documented locally advanced or metastatic solid tumor
-
Refractory or intolerant to all available standard-of-care therapies for advanced disease
-
Measurable disease
-
Adequate tumor sample
-
ECOG Performance Status of 0 or 1
-
BMI ≥ 18 kg/m2
-
Adequate liver, renal, hematologic, and coagulation parameters
-
Negative serum pregnancy test (for women of childbearing potential) at Screening and a negative urine or serum pregnancy test on Day 1 prior to the first infusion
-
Males and females of childbearing potential must agree to use a highly effective method of contraception during treatment and for at least 4 months after the last dose of study treatment.
-
Must be able to understand and comply with the conditions of the protocol and must have read and understood the consent form and provided written informed consent.
Exclusion Criteria:
-
Concurrent anticancer therapy: Radiotherapy, chemotherapy, biological therapy, or other anticancer investigational agents NOTE: at least 5 half-lives must have been ensued for any prior systemic cancer therapy agent before subject received the study drug on Day 1
-
Unresolved toxicities from prior anticancer therapy, defined as not having resolved according to CTCAE version 5.0 Grade ≤ 1, excluding Grade 1 alopecia
-
Presence or suspicion of active central nervous system (CNS) metastases and/or leptomeningeal carcinomatosis
-
Peripheral neurotoxicity ≥ Grade 2 according to CTCAE v5.0
-
Known active infection with HIV, HTLV-1, hepatitis B or C
-
Women who are pregnant or breastfeeding
-
History of another malignancy unless the subject has been treated with curative intent for this malignancy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Emory University Winship Cancer Institute | Atlanta | Georgia | United States | 30322 |
| 2 | Horizon Oncology and Research Center | Lafayette | Indiana | United States | 47905 |
| 3 | Weill Cornell - NY Presbyterian Hospital | New York | New York | United States | 10065 |
| 4 | Pennsylvania Cancer Specialists & Research Institute | Gettysburg | Pennsylvania | United States | 17325 |
Sponsors and Collaborators
- Ranok Therapuetics Co. Ltd.
Investigators
- Study Director: Joelle Lufkin, Ranok Therapeutics
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RNK05047-01